FDA Brief

Company record

Similasan AG

1 FDA warning letter since 2023 and 0 recalls in the last 12 months.

Get an email the day FDA posts anything new about Similasan AG.

Warning letters

  1. Similasan AG

    Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.

    High risk